DOSAGE / 04
BPC-157 TB-500 Dosage: What the Research Literature Recorded
There is no validated human dose for either constituent or the blend. This page documents the animal-model parameters used in the underlying studies — research-handling context, not human-use guidance.
BPC-157 and TB-500 Dosage in the Research Literature
BPC-157 TB-500 dosage, as it appears in the peer-reviewed record, is a set of animal-model parameters — not a human regimen. There is no validated dose for the blend, and there is no controlled combination dose-finding study [11]. Everything below is the research-context BPC-157 and TB-500 dosage in animal models, framed as "studied at X in [species]."
The BPC-157 component, in rodent models, was commonly expressed per body weight — frequently ~10 microg/kg and ~10 ng/kg, with gastric-ulcer cytoprotection studied at 400-800 ng/kg in rats [5][1]. The TB-500 / Thymosin Beta-4 component spanned a wide range — for example 2-18 mg/kg intraperitoneal in a rat embolic-stroke dose-response study (with the highest 18 mg/kg dose giving no benefit, so higher was not better), and 150 microg twice weekly intraperitoneally for 6 months in the mdx muscular-dystrophy study [4]. Commercial vials commonly pair fixed combined masses — for example 10 mg plus 10 mg — but no peer-reviewed combination dose-finding study supports any such figure [11].
Half-Life and Pharmacokinetics
What is the half-life of BPC-157 and TB-500?
No validated human half-life exists for either constituent or the blend. BPC-157's elimination half-life was reported under 30 minutes in a rat/dog pharmacokinetic study [1]. Human intravenous Thymosin Beta-4 showed dose-proportional pharmacokinetics with half-life increasing at higher doses, but no specific half-life is established for the TB-500 heptapeptide [14].
The half-life and pharmacokinetics picture, in short, is anchored on animal and full-length-protein data only. The blend has no characterized pharmacokinetic profile of its own.
Oral vs Injectable BPC-157 and TB-500 in Research Handling
BPC-157 TB-500 oral and injectable routes
BPC-157 is studied as a "stable gastric" peptide, and oral and peroral routes appear in its individual-compound literature [1]. The predominant routes in the underlying rodent efficacy studies were intraperitoneal for both peptides; intravenous appears in the human Phase 1 work on full-length Thymosin Beta-4 and a BPC-157 intravenous safety pilot [14]. Oral blend products are marketed but lack validated pharmacokinetics. None of these routes derives from a controlled human efficacy trial of the combination [11].
How the Wolverine Blend Is Administered in Research Protocols
Wolverine injection and administration routes
Subcutaneous and intramuscular administration are the predominant research-community routes for the blend, but these are not derived from controlled human efficacy trials [11]. There is no validated blend injection schedule.
How often should you inject BPC-157 and TB-500?
There is no validated injection schedule for the blend. Underlying rodent studies used a range of dosing — for example TB-500 / Thymosin Beta-4 at 150 microg twice weekly intraperitoneally for 6 months in one model — and community "loading then maintenance" protocols have no controlled-trial basis [4][11].
How do you reconstitute a BPC-157 / TB-500 blend (10mg)?
Both constituents are supplied as lyophilized powders for research use, reconstituted in bacteriostatic or sterile water and refrigerated. Product identity, purity and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed. This is research-handling context, not a human-use instruction.
How do you cycle BPC-157 and TB-500?
No validated cycle exists. Community "loading then maintenance" protocols and fixed-ratio vials — for example 10 mg plus 10 mg — have no basis in controlled human trials and should not be presented as validated dosing [11]. Underlying study durations vary widely by model.